Loading clinical trials...
Loading clinical trials...
The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza antige...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
Collaborators
NCT00841763 · Pandemic Influenza Disease
NCT00992212 · Pandemic Influenza Disease
G. D'Annunzio University
Chieti
Department of Health Sciences
Genoa
ASL Lanciano-Vasto
Lanciano
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions